Meridian Bioscience Inc. (NASDAQ:VIVO) went up by 3.73% during the previous trading session, and it is maintaining the win ahead of Wednesday’s trading session. The share price of the Diagnostics & Research giant went up by $24.48 to trade ended Wednesday trading at $23.60. This is up from the $23.6 price recorded on Tuesday’s trading session. Thanks to this latest performance, VIVO is closer to the higher price 52-week target of $19.00 and further from the lowest price target of $19.00. Its performance from the start of the year has also been positive, with VIVO up by 150.56% year-to-date.
Meridian Bioscience Inc. (VIVO) started the day trading at $23.71 and recorded an intraday high of $24.75. It also recorded an intraday low of $23.69 during Wednesday’s trading session. Meridian Bioscience Inc. is a very active stock that recorded a trading volume that is less than -34.69% of the average daily trading volume on Wednesday. The stock’s trading volume on Wednesday was 677237, which is less than -34.69 of the total average daily trading volume of 912.15K.
Meridian Bioscience Inc. (NASDAQ:VIVO) 2020 Performance Impressive
The increase in VIVO’s stock price on Wednesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of VIVO currently stands at $24.94, which is higher than the current trading price of the stock by 1.84%. However, VIVO’s current trading price is -344.28% lower than the 52-week low price of $5.51. In terms of trading volume, Meridian Bioscience Inc. currently experienced healthy participation during the last trading session. 677237 shares of Meridian Bioscience Inc. were traded on the stock exchange on Wednesday, which is less than -34.69% of the 912.15K average trading volume of the stock.
The performance of the stock has been positive over the past year. VIVO’s performance over the past one year has seen it surge by 111.58%, while the stock has gone up by 149.67% in the last six months. The quarterly performance of VIVO currently stands at 182.35%, and it is up by 48.09% in the last month. The only positive figure was from the weekly performance, which currently reads 5.11%. At the time of writing VIVO’s report, the company has a total market cap of $1.00B, making it one of the largest publicly-traded companies in the world.Meridian Bioscience Inc. also has over 660 employees all over the world.
VIVO Insider Activities
For Meridian Bioscience Inc., insiders hold 85.30% of all company shares. The insider transactions over the past six months are up by 17.80%. During that period, insiders bought 75,598 shares in 16 transactions. In that same period, insiders sold 1,583 of their shares in 2 transactions. After these transactions, insiders at Meridian Bioscience Inc. now hold 499.86k shares, which is over 87.16% of the total company stocks. Institutional investors currently hold a large chunk of the VIVO shares, as they control 1.17% of the company’s total stock.
VIVO Fundamental Analysis
For Meridian Bioscience Inc., the stock’s diluted earnings per share (EPS) stands at 0.50. In the coming year, analysts expect the EPS to be 1.02. The EPS growth will up over the next five years to 17.00% after plunging by -7.30% in the previous five years. In terms of revenue, Meridian Bioscience Inc.’s quarterly sales (YOY) is growing at 0.25, which is higher than the average annual revenue of -7.30% over the past half a decade.
The Return on Investment (ROI) on Meridian Bioscience Inc.’s stock currently stands at 9.60%, and it has a net profit margin of 10.50%. The operating margin of the company is 14.40%, and its gross margin is 58.50%.
VIVO Analysts Prediction
The Piper Jaffray has a Neutral rating for Meridian Bioscience Inc., predicting the stock price to stay between $15 and $11. Another analyst that has a Sell rating for VIVO is Canaccord Genuity, which set a price target of between $17 and $11. Canaccord Genuity reiterate their Hold position on the stock ($14 and $16)
Analysts at Canaccord Genuity believe that VIVO is Hold, and they have a price target of between $18 and $19. VIVO received a positive rating from Canaccord Genuity, which set a price target of $19-$18 for the stock.
VIVO Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of VIVO currently stands at 22.87%, while the SMA50 is 45.51%. The biggest one is the SMA200, which is currently reading 122.66% ahead of Wednesday’s trading session. The Relative Strength Index of this stock is 73.06, while its price to earnings ratio (P/E) is 49.16.